Cardiovascular Risk Profile in Prostate Cancer Patients Treated with GnRH Agonists versus Antagonists: An Italian Real-World Analysis

References

• Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–642. doi:10.1016/j.eururo.2016.08.002
   PubMed Web of Science ®Google Scholar
• Morgia G, Russo GI, Tubaro A, et al. Prevalence of cardiovascular disease and osteoporosis during androgen deprivation therapy prescription discordant to EAU guidelines: results from a multicenter, cross-sectional analysis from the CHOsIng Treatment for Prostate canCEr (CHOICE) study. Urology. 2016;96:165–170. doi:10.1016/j.urology.2016.06.024
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–836. doi:10.1016/j.eururo.2014.07.010
   PubMed Web of Science ®Google Scholar
• Lomax AJ, Parente P, Gilfillan C, Livingston PM, Davis ID, Pezaro C. “First, do no harm”: managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer. Intern Med J. 2016;46(2):141–148. doi:10.1111/imj.12731
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396. doi:10.1016/j.eururo.2014.11.039
   PubMed Web of Science ®Google Scholar
• Haque R, UlcickasYood M, Xu X, et al. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017;117(8):1233–1240. doi:10.1038/bjc.2017.280
   PubMed Web of Science ®Google Scholar
• O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. JCO. 2015;33(11):1243–1251. doi:10.1200/JCO.2014.59.1792
   PubMed Web of Science ®Google Scholar
• Ziehr DR, Chen M-H, Zhang D, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116(3):358–365. doi:10.1111/bju.12905
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Sun M, Popa I, et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. Clin Genitourin Cancer. 2015;13(3):e123–e130. doi:10.1016/j.clgc.2014.12.003
   PubMed Web of Science ®Google Scholar
• Gupta D, Salmane C, Slovin S, Steingart RM. Cardiovascular complications of androgen deprivation therapy for prostate cancer. Curr Treat Options Cardiovasc Med. 2017;19(8):61. doi:10.1007/s11936-017-0563-1
   PubMedGoogle Scholar
• Nguyen PL, Je Y, Schutz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–2366. doi:10.1001/jama.2011.1745
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. FDA; June 2019. Available from:http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification. Accessed July 15, 2019..
   Google Scholar
• Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–573. doi:10.1016/j.eururo.2013.10.032
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines; 2010. Available from:https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdf.
   Google Scholar
• Zareba P, Duivenvoorden W, Leong DP, Pinthus JH. Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol. 2016;8(2):118–129. doi:10.1177/1756287215617872
   PubMed Web of Science ®Google Scholar
• Tivesten Å, Pinthus JH, Clarke N, Duivenvoorden W, Nilsson J. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms. Urol Oncol. 2015;33(11):464–475. doi:10.1016/j.urolonc.2015.05.030
   PubMed Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–1630. doi:10.1056/NEJMoa1001283
   PubMed Web of Science ®Google Scholar
• Dong F, Skinner DC, Wu TJ, Ren J. The heart: a novel gonadotrophin-releasing hormone target. J Neuroendocrinol. 2011;23(5):456–463. doi:10.1111/j.1365-2826.2011.02119.x
   PubMed Web of Science ®Google Scholar
• Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urology. 2019;202(6):1199–1208. doi:10.1097/JU.0000000000000384
   PubMed Web of Science ®Google Scholar
• Chen HF, Jeung EB, Stephenson M, Leung PC. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999;84(2):743–750. doi:10.1210/jcem.84.2.5440
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27(1):92–99. doi:10.1200/JCO.2007.12.3752
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–1073. doi:10.1016/S1470-2045(10)70223-0
   PubMed Web of Science ®Google Scholar
• Merseburger AS, Sedding D, Hüter K. Kardiovaskuläre Risikopatienten unter Androgenentzugstherapie. [Cardiovascular risk patients under androgen deprivation therapy: lower risk with GnRH antagonists compared to LHRH agonists?]. Urologe A. 2016;55(2):218–225. doi:10.1007/s00120-015-0013-1.German.
   PubMedGoogle Scholar
• Scailteux L-M, Vincendeau S, Balusson F, et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists—a nationwide population-based cohort study based on 2010–2013 French Health Insurance data. Eur J Cancer. 2017;77:99–108. doi:10.1016/j.ejca.2017.03.002
   PubMed Web of Science ®Google Scholar
• Albertsen PC. Re: androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists. Eur J Cancer. 2017;87:203. doi:10.1016/j.ejca.2017.06.041
   PubMed Web of Science ®Google Scholar